🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
ABBV
NYSE
🇺🇸 US
AbbVie Inc.
Pharmaceuticals
17Score
DipBuster Score™
$253.38
$1.11 (0%)
Live price · Source: FMP-live
52-Week Position
$184.63
89% of range
$261.64
Beta
0.283
Low vol
Dividend
—
no income
Mkt Cap
$447.67B
total value
Mkt Cap$447.67B
P/EN/A
DividendNone
Beta0.283
52W High$261.64
52W Low$184.63
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 89% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt Cap$447.67B
52W Position89% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.283
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at AbbVie Inc. (ABBV), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-30 | Quaggin Susan E | BUY | 62 |
| 2026-06-30 | Rapp Edward J | BUY | 134 |
| 2026-05-08 | Quaggin Susan E | BUY | 1,118 |
| 2026-05-08 | Davis Jennifer L. | BUY | 1,118 |
| 2026-05-08 | Meyer Melody B | BUY | 1,118 |
| 2026-05-08 | Burnside William H.l. | BUY | 1,118 |
| 2026-05-08 | Hart Brett J | BUY | 1,118 |
| 2026-05-08 | Roberts Rebecca B | BUY | 1,118 |
| 2026-05-08 | Freyman Thomas C | BUY | 1,118 |
| 2026-05-08 | Waddell Frederick H | BUY | 1,118 |
Valuation
P/E RatioN/A
Market Cap$447.67B
Beta0.283
Dividend/yrNone
52W High$261.64
52W Low$184.63
52-Week Range
$184.63Now$261.64
89% through annual range
From 52W High−3.2%
From 52W Low+37.2%
📖 Plain English Summary
AbbVie Inc. is at 89% of its 52-week range. Beta 0.283 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for ABBV
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — ABBV
Heuristic · balance sheet, insider filings, price data, academic research
AbbVie Inc. — DipBuster Score 17/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track AbbVie Inc. free
Add ABBV to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
4/25
Momentum & Volume
8/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 17/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Im…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Robert A. Michael
Staff
57,000 employees
Website